Skip to main
LFCR

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical is projected to demonstrate significant financial growth with EBITDA expected to increase from $25.1 million, representing a 16.8% margin in FY26, to $27.3 million, indicating a 19.1% margin in FY27. The company also reported a positive shift in free cash flow, expected to grow from $5.1 million in FY26 to $6.0 million in FY27. These metrics highlight Lifecore's enhanced profitability and efficient cash management, supporting a positive outlook for the company’s financial performance.

Bears say

Lifecore Biomedical Inc faces challenges due to the anticipated market growth for the fill/finish segment being slightly below expectations, influenced by the inclusion of small molecule injectables, which dampens revenue potential. The company is projected to experience a high leverage ratio alongside a lack of meaningful revenue growth until calendar year 2027, raising concerns about its financial health and investment appeal. Consequently, this combination of factors supports a negative outlook, suggesting that a discount to peer valuations is justified.

LFCR has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Hold based on their latest research and market trends.

According to 1 analysts, LFCR has a Hold consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.